Calendar Opportunities Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2025 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

biphasic insulin aspart - Phase 3 | NVO Pipeline | CatalystAlert

biphasic insulin aspart

Phase 3

Novo Nordisk A/S (NVO)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

6

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Diabetes

Clinical Trial

Last updated: 12/8/2025

Regulatory Approvals

EMA

4/25/2022

Truvelog Mix 30

Truvelog Mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

EMA2/5/2021

Kirsty (previously Kixelle)

Kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

EMA6/25/2020

Insulin aspart Sanofi

Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

EMA1/9/2017

Fiasp

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

EMA8/1/2000

NovoMix

Treatment of diabetes mellitus.

EMA9/7/1999

NovoRapid

NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Developer

NVO

Novo Nordisk A/S

Biotechnology•Europe•NYSE

Related Pipeline

sitagliptinPhase 3

Diabetes

biphasic human insulinPhase 3

Diabetes

Semaglutide 1.0 mgPhase 3

Obesity

CagrilintidePhase 3

Obesity or Overweight

Insulin IcodecPhase 3

Diabetes Mellitus, Type 2

View full pipeline